Purpose: To retrospectively study the efficacy of a single 0.7-mg dexamethasone intravitreal implant in eyes with refractory macular edema secondary to uncomplicated phacoemulsification and intraocular lens implant. Methods: In 11 eyes of 11 consecutive patients with persistent refractory macular edema, secondary uncomplicated cataract extraction, and intraocular lens implant, the injection of 0.7-mg dexamethasone implant was performed at the Clinica Oculistica, University of Bari, Italy. Best-corrected visual acuity (BCVA), central retinal thickness measured by spectral-domain optical coherence tomography, and intraocular pressure (IOP) was evaluated at baseline, 1 month, and 6 months. Results: After a mean follow-up of 6.27 ± 0.47 months, BCVA was significantly increased from 20/40 to 20/22 (p<0.0001), mean central retinal thickness decreased significantly from 462 ± 100 to 276 ± 8 μm (p<0.0001), and IOP did not change significantly (p = 0.053). In no case were postoperative complications observed. Conclusions: A single injection of 0.7-mg dexamethasone intravitreal implant was effective in the treatment of persistent refractory macular edema secondary to uneventful phacoemulsification and in-bag lens implant. © 2013 Wichtig Editore.

Purpose: To retrospectively study the efficacy of a single 0.7-mg dexamethasone intravitreal implant in eyes with refractory macular edema secondary to uncomplicated phacoemulsification and intraocular lens implant.Methods: In 11 eyes of 11 consecutive patients with persistent refractory macular edema, secondary uncomplicated cataract extraction, and intraocular lens implant, the injection of 0.7-mg dexamethasone implant was performed at the Clinica Oculistica, University of Bari, Italy. Best-corrected visual acuity (BCVA), central retinal thickness measured by spectral-domain optical coherence tomography, and intraocular pressure (IOP) was evaluated at baseline, 1 month, and 6 months.Results: After a mean follow-up of 6.27 ± 0.47 months, BCVA was significantly increased from 20/40 to 20/22 (p<0.0001), mean central retinal thickness decreased significantly from 462 ± 100 to 276 ± 8 µm (p<0.0001), and IOP did not change significantly (p = 0.053). In no case were postoperative complications observed.Conclusions: A single injection of 0.7-mg dexamethasone intravitreal implant was effective in the treatment of persistent refractory macular edema secondary to uneventful phacoemulsification and in-bag lens implant.

Intravitreal dexamethasone implant for macular edema following uncomplicated phacoemulsification / Furino, C; Boscia, Francesco; Recchimurzo, F.; Sborgia, N; Alessio, C.. - In: EUROPEAN JOURNAL OF OPHTHALMOLOGY. - ISSN 1120-6721. - 24:3(2014), pp. 387-391. [10.5301/ejo.5000375]

Intravitreal dexamethasone implant for macular edema following uncomplicated phacoemulsification

BOSCIA, Francesco;
2014-01-01

Abstract

Purpose: To retrospectively study the efficacy of a single 0.7-mg dexamethasone intravitreal implant in eyes with refractory macular edema secondary to uncomplicated phacoemulsification and intraocular lens implant.Methods: In 11 eyes of 11 consecutive patients with persistent refractory macular edema, secondary uncomplicated cataract extraction, and intraocular lens implant, the injection of 0.7-mg dexamethasone implant was performed at the Clinica Oculistica, University of Bari, Italy. Best-corrected visual acuity (BCVA), central retinal thickness measured by spectral-domain optical coherence tomography, and intraocular pressure (IOP) was evaluated at baseline, 1 month, and 6 months.Results: After a mean follow-up of 6.27 ± 0.47 months, BCVA was significantly increased from 20/40 to 20/22 (p<0.0001), mean central retinal thickness decreased significantly from 462 ± 100 to 276 ± 8 µm (p<0.0001), and IOP did not change significantly (p = 0.053). In no case were postoperative complications observed.Conclusions: A single injection of 0.7-mg dexamethasone intravitreal implant was effective in the treatment of persistent refractory macular edema secondary to uneventful phacoemulsification and in-bag lens implant.
2014
Inglese
24
3
387
391
5
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84899641127&doi=10.5301%2fejo.5000375&partnerID=40&md5=fb93d0b7b97018df7972d29d5d99483f
Purpose: To retrospectively study the efficacy of a single 0.7-mg dexamethasone intravitreal implant in eyes with refractory macular edema secondary to uncomplicated phacoemulsification and intraocular lens implant. Methods: In 11 eyes of 11 consecutive patients with persistent refractory macular edema, secondary uncomplicated cataract extraction, and intraocular lens implant, the injection of 0.7-mg dexamethasone implant was performed at the Clinica Oculistica, University of Bari, Italy. Best-corrected visual acuity (BCVA), central retinal thickness measured by spectral-domain optical coherence tomography, and intraocular pressure (IOP) was evaluated at baseline, 1 month, and 6 months. Results: After a mean follow-up of 6.27 ± 0.47 months, BCVA was significantly increased from 20/40 to 20/22 (p<0.0001), mean central retinal thickness decreased significantly from 462 ± 100 to 276 ± 8 μm (p<0.0001), and IOP did not change significantly (p = 0.053). In no case were postoperative complications observed. Conclusions: A single injection of 0.7-mg dexamethasone intravitreal implant was effective in the treatment of persistent refractory macular edema secondary to uneventful phacoemulsification and in-bag lens implant. © 2013 Wichtig Editore.
dexamethasone, article; central retinal thickness; clinical article; follow up; human; intraocular pressure; intravitreal implant; phacoemulsification; priority journal; retina macula edema; retrospective study; single drug dose; spectral domain optical coherence tomography; visual acuity, Adult; Aged; Dexamethasone; Drug Implants; Female; Glucocorticoids; Humans; Intraocular Pressure; Lens Implantation, Intraocular; Lenses, Intraocular; Macular Edema; Male; Middle Aged; Phacoemulsification; Postoperative Complications; Retrospective Studies; Tomography, Optical Coherence; Visual Acuity; Vitreous Body; Dexamethasone; Intravitreal implant; Irvine-gass syndrome; Macular edema; Ozurdex
Furino, C; Boscia, Francesco; Recchimurzo, F.; Sborgia, N; Alessio, C.
Intravitreal dexamethasone implant for macular edema following uncomplicated phacoemulsification / Furino, C; Boscia, Francesco; Recchimurzo, F.; Sborgia, N; Alessio, C.. - In: EUROPEAN JOURNAL OF OPHTHALMOLOGY. - ISSN 1120-6721. - 24:3(2014), pp. 387-391. [10.5301/ejo.5000375]
info:eu-repo/semantics/article
1 Contributo su Rivista::1.1 Articolo in rivista
262
5
none
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11388/178105
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 14
  • ???jsp.display-item.citation.isi??? ND
social impact